XENOTHERA

XENOTHERA is a biotechnology startup based in Nantes, France, that specializes in glyco-humanized polyclonal antibody therapies. The company leverages animal genetics and immunological expertise to develop innovative treatments for various medical fields, including immunomodulation, infectious diseases, oncology, transplantation, and onco-hematology. Founded with a focus on genetically modified pigs for therapeutic applications, XENOTHERA aims to enhance passive immunotherapy through engineered hyperimmune polyclonal sera.

The company’s glyco-humanized antibody platform produces next-generation antibodies with optimized glycosylation, improving efficacy in immunotherapy. XENOTHERA's pipeline includes several promising candidates, such as XAV-19 for COVID-19, XAB-05 for bacterial infections, and LIS1 for peripheral T-cell lymphoma, among others. The company actively conducts clinical trials and emphasizes patient access, while also engaging in research related to xenotransplantation for organ therapies. With a commitment to agile development, XENOTHERA is supported by significant funding and has made notable advancements in its therapeutic offerings.